Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint - Biogen (NASDAQ:BIIB) - Press Release
Showing Highly Statistically Significant Reduction of Clinical Decline in Large Global Clinical Study of 1,795 Participants With Early Alzheimer's Dis
Source: wiredprnews.com